All News

Why do patients drop drug therapy after 12 months?

If there was ever a justification for endorsing a "triple bottom line" strategy for measuring Big Pharma's investment performance, it's the BP crisis.

GSK's blockbuster diabetes drug Avandia was the subject of a number of studies this week offering good and bad news. But the company's big challenge is going to be FDA's advisory review panel set to meet in two short weeks.

Emerging Pharma Leaders 2010

FDA's meeting on the adoption of REMS for certain prescription opioids doesn't begin until July 22, but the agency's proposal released Tuesday portends a meeting fraught with conflict over the balance between curbing abuse and protecting patient access.

Country Reports Columbia

Country Reports Germany

Pfizer was forced (voluntarily) to put the kibosh on a fast-tracked Wyeth drug after some not-so-favorable postmarket data. Was this a good catch or an endemic problem with expedited drugs?

A new study indicates that doctors are no longer switching offices - largely due to current economic woes. What does this mean for sales reps? Pharm Exec interviews SK&A to find out more about its survey.

Mark Gordon looks at how real partnership opportunities are developing in a virtual pharma world.

Merck has established a stable of 15 to 20 investigators focused solely on cancer compounds in an effort to boost efficiency and help move along the bevy of oncology products the firm has in its pipeline.

A heavily rigid agency network structure that fights against their strategic objectives is the last thing clients should be looking for.

The trend is strong, bold ideas that travel across cultures.

With so much variation, why force local affiliates to use the global agency?This is a battle seldom worth the fight.

We need to start thinking of digital as part of a marketing plan instead of The Plan.

An ideal partner is one that will work with manufacturers on a variable cost basis, providing the ability to scale resources up and down as new products are introduced and marketing and sales needs change.

To assume that growing a marketing presence in emerging markets automatically requires a global agency network is a flawed assumption.

Sure, there might be a few key audiences whose view of your reputation is critical, but targeting them is fairly simple and often inexpensive. More times than not, it's better to keep your head down than raise the banner and lead the field.

Hot topics in the pharma advertising world and covered in this year's Agency Confidential include marketing drugs in emerging countries, and why you shouldn't worry about what people say about your company.

Two of the most essential supplies we can offer emerging regions are infrastructure support and easier access to health information

Independence equals creativity, and solutions

Strategy-listening, seeing, thinking-all need to be done locally.

New high-growth markets are reflecting an unprecedented shift of industry growth to the world's emerging economies. How are Pharma's agencies coping?

The monolithic dictates out of marketing and agency headquarters in New York and London-and the way they are forced on local marketing efforts-work to undermine adoption at the local level

A global agency has the highest chance of ensuring core brand value

In China people view expenditures on pharmaceuticals as a "cost" rather than a "purchase"

The pharma industry has only recently seen the kinds of price pressures that the retail industry has operated under for decades.

The companies with the best corporate reputations have responsibility initiatives that earn their way, but very few of them started in response to a perceived problem or a bit of bad press.

After an active campaign spanning nearly six years, the epidemiology data showed a decline in the number of patients with Hep B, from 1.3 million to 0.9 million.

Emerging Pharma Leaders